 Home > Active Ingredient News > Antitumor Therapy > Amgen KRAS Inhibitor Meets Primary Endpoint of First Randomized Controlled Clinical Trial for the Treatment of Non-Small Cell Lung Cancer

Amgen KRAS Inhibitor Meets Primary Endpoint of First Randomized Controlled Clinical Trial for the Treatment of Non-Small Cell Lung Cancer

 Last Update: 2022-09-08
 Source: Internet
 Author: User

▎Edited by WuXi AppTec Content Team

Today, Amgen announced that its KRAS G12C inhibitor, Lumakras (sotorasib), met its primary endpoint in a Phase 3 clinical trial in patients with previously treated non-small cell lung cancer harboring a KRAS G12C mutation, compared with standard chemotherapy.

The KRAS gene mutation is one of the most common oncogene mutations in cancer patients, and it was once a well-known "undruggable" target

Amgen said the trial met its primary endpoint, with Lumakras showing superiority over intravenous docetaxel, with statistically significant improvements in patients' PFS

▲If you have any business needs, please long press to scan the QR code above, or

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Crocetin27876-94-4

CAS No.: 27876-94-4

$1-1.1/G FOB

Betulinic acid472-15-1

CAS No.: 472-15-1

$1-1.1/G FOB

1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane 53-19-0

CAS No.: 53-19-0

Pharmacy Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.